MEDNAX (MD) Given a $55.00 Price Target at SunTrust Banks

MEDNAX (NYSE:MD) has been assigned a $55.00 price target by equities researchers at SunTrust Banks in a report released on Thursday, December 21st. The brokerage presently has a “hold” rating on the stock. SunTrust Banks’ price objective would indicate a potential upside of 1.44% from the company’s current price.

Other analysts have also issued research reports about the stock. KeyCorp set a $51.00 price objective on shares of MEDNAX and gave the stock a “buy” rating in a research report on Wednesday, November 1st. Jefferies Group reaffirmed a “hold” rating and issued a $44.00 price objective on shares of MEDNAX in a research report on Friday, November 3rd. Robert W. Baird reiterated a “hold” rating and issued a $47.00 target price on shares of MEDNAX in a research note on Sunday, September 3rd. Zacks Investment Research upgraded shares of MEDNAX from a “sell” rating to a “hold” rating in a research note on Wednesday, October 11th. Finally, BMO Capital Markets assumed coverage on shares of MEDNAX in a research note on Monday, October 16th. They issued a “market perform” rating and a $46.00 target price for the company. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and three have issued a buy rating to the company. MEDNAX has an average rating of “Hold” and an average target price of $53.82.

MEDNAX (NYSE:MD) traded up $0.05 on Thursday, hitting $54.22. 446,418 shares of the company were exchanged, compared to its average volume of 845,477. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.37 and a quick ratio of 1.37. MEDNAX has a one year low of $40.56 and a one year high of $72.13. The company has a market capitalization of $5,073.30, a price-to-earnings ratio of 19.16, a P/E/G ratio of 1.63 and a beta of 0.39.

MEDNAX (NYSE:MD) last released its quarterly earnings results on Wednesday, November 1st. The company reported $0.87 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.87. The company had revenue of $868.95 million for the quarter, compared to analyst estimates of $864.78 million. MEDNAX had a net margin of 7.76% and a return on equity of 10.80%. The firm’s revenue was up 4.9% on a year-over-year basis. During the same period last year, the firm earned $1.09 earnings per share. analysts predict that MEDNAX will post 3.1 earnings per share for the current year.

In other MEDNAX news, insider John C. Pepia sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $51.58, for a total value of $154,740.00. Following the completion of the transaction, the insider now owns 35,569 shares of the company’s stock, valued at approximately $1,834,649.02. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Cesar L. Alvarez sold 10,668 shares of the business’s stock in a transaction that occurred on Friday, November 3rd. The stock was sold at an average price of $42.59, for a total transaction of $454,350.12. Following the completion of the sale, the director now owns 44,215 shares of the company’s stock, valued at $1,883,116.85. The disclosure for this sale can be found here. 2.40% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently made changes to their positions in the company. Prudential Financial Inc. lifted its holdings in shares of MEDNAX by 976.9% in the 3rd quarter. Prudential Financial Inc. now owns 641,057 shares of the company’s stock worth $27,642,000 after acquiring an additional 581,527 shares during the last quarter. Eagle Boston Investment Management Inc. raised its holdings in MEDNAX by 12.9% during the 2nd quarter. Eagle Boston Investment Management Inc. now owns 191,636 shares of the company’s stock valued at $11,569,000 after buying an additional 21,895 shares during the last quarter. Quantbot Technologies LP bought a new stake in MEDNAX during the 3rd quarter valued at $695,000. Swiss National Bank raised its holdings in MEDNAX by 3.0% during the 2nd quarter. Swiss National Bank now owns 341,700 shares of the company’s stock valued at $20,628,000 after buying an additional 9,900 shares during the last quarter. Finally, Nomura Holdings Inc. bought a new stake in MEDNAX during the 2nd quarter valued at $347,000. Hedge funds and other institutional investors own 98.43% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/01/13/mednax-md-given-a-55-00-price-target-at-suntrust-banks.html.

About MEDNAX

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Analyst Recommendations for MEDNAX (NYSE:MD)

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply